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nists were used more often as first-line medical therapy.
The probability of first-line success has been estimated at
71.2% for common practice and 72.3% for best practice.
CONCLUSION: Despite higher surgical costs and im-
proved outcomes associated with best practice manage-
ment of POAG as compared with common practice, to-
tal, drug, and medical care costs of best practice were
comparable to those of common practice.
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FOUR YEAR COST-EFFECTIVENESS OF INITIAL 
TRABECULECTOMY VERSUS CONVENTIONAL 
THERAPY IN PRIMARY OPEN-ANGLE 
GLAUCOMA (POAG)
Yu E, Hay J, Varma R, Globe D
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To determine the cost-effectiveness of the
primary treatment of primary open-angle glaucoma
(POAG) with trabeculectomy versus conventional ther-
apy. METHODS: A four-year incremental cost/quality-
adjusted life year (QALY) model (year 2000 US dollars)
of POAG using a societal perspective; including direct
and indirect costs with a 3% annual discount rate for the
base case. In the Glasgow trial, patients newly diagnosed
with POAG with an intraocular pressure of 26mmHg
and/or with glaucomatous field defects were randomized
to trabeculectomy or conventional therapy (up to three
medications). In the trabeculectomy branch, patients
would either be 1) controlled without extra medication,
2) controlled with extra medication or 3) die from natu-
ral causes. Annual chance nodes for the conventional
were 1) controlled by medication, 2) surgery or 3) death
from natural causes. QALYs were calculated assuming a
decline in utility would accompany loss in visual field. A
65-year old patient with a 5% rate of decline in utility
was used as the base case. Sensitivity analyses were per-
formed on the rate of utility decline, cost of medications,
trabeculectomy cost, and discount rate. RESULTS: For
the base case, the cost of initial trabeculectomy was
$8316 versus $6339 for conventional therapy. The incre-
mental cost was $1977 and the incremental QALY was
0.08, with ICE ratio of $24,830/QALY. CONCLU-
SIONS: Initial trabeculectomy is cost-effective for POAG.
The model was most sensitive to the rate of decline in
utility (2%) and robust to changes in the costs of medi-
cations and trabeculectomy. Limitations include the lack
of long-term clinical and QALY data on glaucoma pa-
tients with different treatments. Currently the standard of
practice in the US is to start with conventional therapy
for patients with moderate or severe glaucoma. Our re-
sults indicate that trabeculectomy may be a cost-effective
option for these patients.
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EFFECTS ON HEALTH CARE CONTACTS AND 
DAYS ABSENT FROM WORK WITH 
BUDESONIDE CIR CAPSULES IN THE 
MAINTENANCE TREATMENT OF CROHN’S 
DISEASE IN A US SETTING
Ericsson K, Borg S
AstraZeneca R&D Lund, Lund, Sweden
INTRODUCTION: Crohn’s disease (CD) is a debilitat-
ing chronic disease. It also has economic implications
(both for patient and society). Reduced work (or school)
attendance and continuous need for health care contacts
are two important aspects. Data comparing the impact of
different treatment approaches are scarce. OBJECTIVE:
To assess health care utilisation and absence for work (or
school) in a US setting of patients treated with budes-
onide CIR maintenance therapy compared to patients
with no maintenance treatment (placebo). A societal per-
spective was adopted. METHODS: Data was collected in
a double-blind randomised clinical trial comparing
budesonide CIR 6 mg daily with placebo for a one year
period. Patients, 55 in each group, had CD localised to
the distal ileum and/or the ascending colon and were be-
tween the ages of 18 and 73 (mean 40.3 and 40.5 years).
The collected data included physician visits, different mi-
nor procedures (e.g., radiographic, endoscopic), medica-
tions, hospitalisations and surgical procedures. Number
of days of absence due to symptoms or treatment of the
disease was also collected. All resource utilisation related
to the design of the clinical trial was excluded in order
not to overestimate real health care use and productivity
losses. RESULTS: The budesonide CIR treatment group
had 26.3% fewer physician visits (87.14 vs. 118.27 ns)
and 27% fewer days absent from work or school (311.73
vs. 427.23 days ns). Numerical differences in other vari-
ables were smaller but in favour of budesonide CIR.
CONCLUSION: Treatment with budesonide CIR cap-
sules suggests benefits in terms of reduced health care re-
source utilisation and absence from work (school), that
also could represent favourable cost implications in the
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OBJECTIVE:To compare the cost-effectiveness of alter-
native dyspepsia management strategies: (1) H. pylori
testing; if seropositive, providing H. pylori eradication
treatment using oral omeprazole, clarithromycin, and
amoxicillin; (2) empiric antisecretory therapy using ome-
prazole. METHODS: Decision analytical models com-
pared cost/QALY for alternative strategies in patients
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grouped by gender and age. The study was conducted
from the societal perspective using Year 1996–1999
prices, adjusted to year 2000 by CPI. Life expectancies
were adjusted for QOL using the Index of Well-Being.
Probabilities and prices were collected from the litera-
ture, the SEER program, National Vital Statistics, and
BLS. The model considered H. pylori reinfection and gas-
tric carcinogenesis risk over time. One-way sensitivity
analyses were conducted on critical or uncertain parame-
ters and threshold analyses on pivotal parameters. RE-
SULTS: The incremental cost-effectiveness ratio (ICE) for
pooled patients (both genders) decreases with age from
$3,612 per quality adjusted life year (QALY) saved at age
40–44 to the minimum of $200 (dominant) per QALY
saved at age 65–70. After age 70, the ICE increases with
age. Females have higher ICEs than males in every age
subgroup. The ICE was sensitive to discount rate, relative
risk of gastric cancer (GC) in H. pylori infected patients,
cost of treating GC, and cost of empiric antisecretory
therapy, but not to the reinfection rate or infection rate
of H. pylori, the change of the utility rate of GC and the
one-year utility of dyspepsia patient under empiric anti-
secretory therapy. CONCLUSIONS: Taking $50,000/
QALY as the societal ICE threshold, H. pylori screening
and eradication is cost-effective for both genders at any
age group, especially for male patients at older ages. Bet-
ter estimates are needed for certain key parameters such
as the relative risk reduction of GC with H. pylori eradi-
cation.
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A PROSPECTIVE, RANDOMIZED COST 
ANALYSIS OF MEPERIDINE AND MIDAZOLAM 
VERSUS PROPOFOL FOR COMPLEX UPPER 
ENDOSCOPY PROCEDURES
Shermock KM, Vargo JJ, Zuccaro G, Maurer WG
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OBJECTIVES: Meperidine/midazolam (M/M) and pro-
pofol (P) are clinically effective alternatives for sedation
during endoscopic procedures. Propofol has a higher ac-
quisition cost, but may be associated with cost savings
due to shorter duration of post-procedure care. The ob-
jective of this project was to compare the costs associated
with complex upper endoscopic procedures (ERCP/EUS)
in subjects who received either M/M or propofol.
METHODS: Subjects scheduled for ERCP/EUS were ran-
domized to receive M/M or P during the procedure. A
blinded observer assessed time to recovery using a stan-
dard 10-point postanesthesia recovery score (PARS) ev-
ery 15 minutes. Once a PARS score of 10 was reached,
the study terminated and the subject was discharged from
the recovery ward. The cost of drug (source: Redbook),
an anesthetist for the propofol group (source: Bureau of
Labor Statistics), recovery room personnel costs (source:
Bureau of Labor Statistics), and overhead costs were
compared from the institutional perspective. A sensitivity
analysis was performed by assuming generic drug, a
nurse anesthetist, and licensed practical nurse (LPN) care
in the recovery ward. RESULTS: 33 and 31 subjects were
randomized to receive M/M and P, respectively. There
were no significant differences detected between the
groups in age, gender, case severity, or procedure dura-
tion. P group subjects had a significantly shorter post-
procedure recovery time (19 minutes) compared with
M/M group subjects (71 minutes, p  0.001). Subjects in
the M/M group cost an average of $65 per case, while P
group subjects cost an average of $144 per case (p 
0.001). The sensitivity analysis resulted in an average
cost of $77 per case in the P group and $34 in the M/M
group (p  0.001). CONCLUSIONS: Subjects in the P
group had a significantly shorter post-procedure recovery
time but this did not result in cost savings compared with
subjects treated with M/M.
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HEALTH-RELATED QUALITY OF LIFE (HRQOL) 
DATA REVEAL DIFFERENCES AMONG
CLINICAL “RESPONDERS”
Watson ME, Heath AT, Northcutt AR
GlaxoSmithKline, Research Triangle Park, NC, USA
OBJECTIVES: Treatment effects are often evaluated by
comparing groups in terms of the proportion of “re-
sponders”, i.e., patients who achieve some prospectively
defined outcome. In the absence of additional data, it is
assumed that responders in different treatment groups
achieve comparable benefits and therefore that the treat-
ment benefit is fully described by the responder rates.
This study compared the HRQOL changes of responders
in two treatment groups. METHODS: In two identical
randomized, double-blind, placebo-controlled studies
(S3BA3001; S3BA3002) in women evaluating 12 weeks
of treatment with alosetron 1mg BID, patients completed
the Irritable Bowel Syndrome Quality of Life Question-
naire (IBSQOL) at baseline and at the final treatment
visit. A patient was classified as a responder if she
achieved adequate relief of IBS pain and discomfort on at
least 2 of 4 weeks for all 3 months. This post-hoc analysis
compared responders from the two treatment groups in
terms of IBSQOL change from baseline scores at the final
visit using analysis of covariance. The analysis focused on
patients with diarrhea-predominant IBS. RESULTS: Our
analyses included 154 patients (96 alosetron and 58 pla-
cebo) in S3BA3001 and 172 (110 alosetron and 62 pla-
cebo) in S3BA3002. Compared with placebo responders,
those in the alosetron group had significantly higher (p 
.05) scores on 5 of 9 IBSQOL scales (sleep; energy; physi-
cal functioning, food and role-physical) in S3BA3001 and
on 4 scales (sleep, energy, food and social functioning) in
S3BA3002. CONCLUSIONS: Adequate relief responders
in the alosetron group experienced significantly greater
HRQOL improvements relative to placebo group re-
sponders. This suggests that treatment benefits may be
underestimated when described only in terms of the addi-
tional proportion of responders. Reporting HRQOL dif-
